Access to nonstatin lipid-lowering therapies in patients at high risk of atherosclerotic cardiovascular disease

Circulation

Volumn 135, Issue 22, 2017, Pages 2204-2206

  Knowles, Joshua W ^a,b   Howard, William B ^c   Karayan, Lala ^b   Baum, Seth J ^d   Wilemon, Katherine A ^b   Ballantyne, Christie M ^e   Myers, Kelly D ^c  

^a STANFORD UNIVERSITY   (United States)

^b FH Foundation   (United States)

^c Atomo Health Inc   (United States)

^d Preventive Cardiology Inc   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

atherosclerosis; familial hypercholesterolemia; PCSK9 inhibitor, human

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ARTICLE; BILLING AND CLAIMS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE ACCESS; HIGH RISK PATIENT; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BLOOD; FACTUAL DATABASE; FEMALE; HYPERCHOLESTEROLEMIA; MALE; PATHOPHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; DATABASES, FACTUAL; EZETIMIBE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PROPROTEIN CONVERTASE 9;

EID: 85019976548     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.027705     Document Type: Article

References (5)

1. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF, Wierzbicki AS, American Heart Association Atherosclerosis, Hypertension, and Obesity in Young Committee of Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and Council on Lifestyle and Cardiometabolic Health The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015 132 2167 2192. doi: 10.1161/CIR.0000000000000297.
2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 25 suppl 2 S1 45. doi: 10.1161/01.cir.0000437738.63853.7a.
3. deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW, Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH Registry. Circ Cardiovasc Genet 2016 9 240 249. doi: 10.1161/CIRCGENETICS.116.001381.
4. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN, Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993 72 171 176
5. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Committee FS and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017. doi: 10.1056/NEJMoa1615664.